FR3104438B1 - Formulation pour le bleu de methylene et procede - Google Patents

Formulation pour le bleu de methylene et procede Download PDF

Info

Publication number
FR3104438B1
FR3104438B1 FR1914303A FR1914303A FR3104438B1 FR 3104438 B1 FR3104438 B1 FR 3104438B1 FR 1914303 A FR1914303 A FR 1914303A FR 1914303 A FR1914303 A FR 1914303A FR 3104438 B1 FR3104438 B1 FR 3104438B1
Authority
FR
France
Prior art keywords
grains
formulation
active principle
film
phenothiazine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR1914303A
Other languages
English (en)
Other versions
FR3104438A1 (fr
Inventor
Luc Grislain
Émilie Poupin
Gilles Lemagnen
Pascal Millet
Koffi Kowouvi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre Hospitalier Universitaire de Bordeaux
Universite de Bordeaux
Original Assignee
Centre Hospitalier Universitaire de Bordeaux
Universite de Bordeaux
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre Hospitalier Universitaire de Bordeaux, Universite de Bordeaux filed Critical Centre Hospitalier Universitaire de Bordeaux
Priority to FR1914303A priority Critical patent/FR3104438B1/fr
Priority to PCT/FR2020/052378 priority patent/WO2021116611A1/fr
Publication of FR3104438A1 publication Critical patent/FR3104438A1/fr
Application granted granted Critical
Publication of FR3104438B1 publication Critical patent/FR3104438B1/fr
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention se rapporte à un procédé de fabrication d’une formulation solide gastro-résistante de principe actif à base de phénothiazine, à une formulation obtenue par ce procédé, notamment à une formulation comprenant de 20 à 80% de bleu de méthylène, par exemple sous forme de grains ou de comprimé, ainsi qu’à la formulation de l’invention pour une utilisation comme médicament, notamment dans traitement du paludisme. Le procédé de l’invention comprend (a) l’obtention de grains de principe actif à base de phénothiazine par granulation humide d’un mélange initial comprenant, en % en poids par rapport au poids total du mélange initial de 25 à 85 % de principe actif à base de phénothiazine sous forme de poudre tamisée afin d’éliminer les amas, de 1 à 5 % d’un désintégrant, de 1 à 60 % d’un diluant, et de 1 à 20 % d’un liant ; (b) un séchage des grains de principe actif à base de phénothiazine obtenus ; (c) éventuellement, l’obtention de comprimés par compression des grains de principe actif séchés à partir d’un mélange de compression comprenant en % en poids par rapport au poids total du mélange de 30 à 80 % desdits grains séchés, de 1 à 15 % d’un désintégrant, de 5 à 70% d’un diluant identique ou différent de celui utilisé à l’étape (a), et le reste étant un lubrifiant et un agent d’écoulement ; (d) un pelliculage des grains séchés ou des comprimés au moyen d’un premier agent de pelliculage ; et (e) un pelliculage gastro-résistant desdits grains pelliculés ou comprimés pelliculés obtenus à l’étape (d).
FR1914303A 2019-12-12 2019-12-12 Formulation pour le bleu de methylene et procede Expired - Fee Related FR3104438B1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
FR1914303A FR3104438B1 (fr) 2019-12-12 2019-12-12 Formulation pour le bleu de methylene et procede
PCT/FR2020/052378 WO2021116611A1 (fr) 2019-12-12 2020-12-10 Formulation pour le bleu de methylene et procede

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1914303A FR3104438B1 (fr) 2019-12-12 2019-12-12 Formulation pour le bleu de methylene et procede
FR1914303 2019-12-12

Publications (2)

Publication Number Publication Date
FR3104438A1 FR3104438A1 (fr) 2021-06-18
FR3104438B1 true FR3104438B1 (fr) 2021-11-19

Family

ID=69743504

Family Applications (1)

Application Number Title Priority Date Filing Date
FR1914303A Expired - Fee Related FR3104438B1 (fr) 2019-12-12 2019-12-12 Formulation pour le bleu de methylene et procede

Country Status (2)

Country Link
FR (1) FR3104438B1 (fr)
WO (1) WO2021116611A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024063700A1 (fr) * 2022-09-21 2024-03-28 Yin Sze Loh Formulation orale de diaminophénothiazines et procédés de fabrication et d'utilisation de celle-ci dans le traitement et/ou la prévention de maladies

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007086079A2 (fr) * 2006-01-25 2007-08-02 Astron Research Limited Forme de dose a liberation soutenue de derives de phenothiazine contenant un canalisateur
EP2645994B1 (fr) * 2010-11-30 2017-11-01 WisTa Laboratories Ltd. Formulations comprenant le chlorure de methylthioninium
JP2019535794A (ja) * 2016-11-28 2019-12-12 コスモ・テクノロジーズ・リミテツド 色素を含有する固体経口組成物

Also Published As

Publication number Publication date
FR3104438A1 (fr) 2021-06-18
WO2021116611A1 (fr) 2021-06-17

Similar Documents

Publication Publication Date Title
JP5416586B2 (ja) コーティング製剤の製造方法
JP6030643B2 (ja) ガン細胞の増殖を阻害するアミド誘導体および非金属塩滑沢剤を含む医薬組成物
RU2384328C2 (ru) Галеновы составы органических соединений
EA201892836A1 (ru) Составы 2-[3-[4-амино-3-(2-фтор-4-феноксифенил)пиразол[3,4-d]пиримидин-1-ил]пиперидин-1-карбонил]-4-метил-4-[4-(оксетан-3-ил)пиперазин-1-ил]пент-2-еннитрила с модифицированным высвобождением
PL1931316T3 (pl) Kompozycje farmaceutyczne o kontrolowanym uwalnianiu dla leków labilnych kwasowo
CA2577288A1 (fr) Chlorhydrate de 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethyl-phenyl]amino]-2-pyrimidinyl]amino]benzonitrile
WO2011025035A1 (fr) Composition de revêtement
FR3104438B1 (fr) Formulation pour le bleu de methylene et procede
FR2677886A1 (fr) Comprime matriciel permettant la liberation prolongee d'indapamide apres administration par voie orale.
CZ299859B6 (cs) Farmaceutická formulace a zpusob její prípravy
US20070134315A1 (en) Orally administrable extended release pellet and tablet formulations of a highly water soluble compound
US10561628B2 (en) Solid preparation including antioxidant
RU2009140792A (ru) Новые стабильные фармацевтические композиции клопидогрель бисульфата и способ их получения
JP2023033395A (ja) ラメルテオン含有フィルムコーティング錠剤
JP2019034929A (ja) エソメプラゾールマグネシウム水和物を含有する腸溶性コーティング製剤、およびその製造方法
RU2011145436A (ru) Композиции с немедленным высвобождением лекарственного средства
JP2017525735A5 (fr)
JP2018500324A5 (fr)
JP2007169273A (ja) 杵付着を改善した医薬製剤
FR3096264B1 (fr) Procédé de préparation de compositions pharmaceutiques contenant des principes actifs amphiphiles
RU2018129198A (ru) Фармацевтические композиции
HRP20120499T1 (hr) Fumarat cijanoetenil dimetilfenil amino pirimidinil amino benzonitrila
JP2016160196A (ja) 非晶質ラロキシフェン塩酸塩含有固体分散体
FR3102931B1 (fr) Procédé de fabrication d’une composition pharmaceutique à administration orale et à délivrance colonique
JP2020143009A (ja) ラメルテオン含有錠剤

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 2

PLSC Publication of the preliminary search report

Effective date: 20210618

PLFP Fee payment

Year of fee payment: 3

ST Notification of lapse

Effective date: 20230808